Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04791358 · ClinicalTrials.gov registry record
Decision Impact Trial of KidneyIntelX
A clinical trial of Diabetic Kidney Disease, sponsored by Renalytix AI.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 1
- Study location
NCT04791358 is a study of Diabetic Kidney Disease that is actively recruiting participants, run by Renalytix AI. The registered enrollment target is 1,500 participants, below the 5,125-participant average among 23 other Diabetic Kidney Disease trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04791358, a study of Diabetic Kidney Disease, is actively recruiting participants, sponsored by Renalytix AI.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 1
- Study location
Study Summary
The current trial is designed to evaluate how the results of KidneyIntelX test impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within 5-years.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST KidneyIntelX
Study Locations (1)
New York
- Delmar Family Medicine - Slingerlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2024-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04791358
The ClinicalTrials.gov registry entry for NCT04791358 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,125-participant average among 23 other Diabetic Kidney Disease trials with a reported enrollment target (71% lower). The listed sponsor is Renalytix AI, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which KidneyIntelX is the first listed.
NCT04791358 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04791358 about?
NCT04791358 is a clinical study titled "Decision Impact Trial of KidneyIntelX". The current trial is designed to evaluate how the results of KidneyIntelX test impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within 5-years.
What is the current status of trial NCT04791358?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2021-11-01. Estimated completion is 2024-12-01.
What conditions does trial NCT04791358 study?
This clinical trial studies the following conditions: Diabetic Kidney Disease.
What interventions are being tested in trial NCT04791358?
The interventions under investigation include: KidneyIntelX (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04791358?
This trial is sponsored by Renalytix AI, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04791358 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
RECRUITING
-
Formoterol in Diabetes
RECRUITING · Phase 2
-
Mechanism of SGLT2 Inhibition in the Kidney
RECRUITING · Phase 4
-
Dosimetry of Tc-99m-Tilmanocept
RECRUITING · Phase 1
-
A Long-Term Follow-Up Study of Participants Exposed to REACT
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.